Начало › Меланом › Масачузетс › Boston
Клинични проучвания за Меланом в Boston, MA
26 проучвания за Меланом търсят участници в обекти в и около Boston (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Набиране на участнициФаза 1/2
- Tufts Medical Center, Boston
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Набиране на участнициФаза 2
- Local Institution - 0124, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
Набиране на участнициФаза 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Набиране на участнициФаза 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Набиране на участнициФаза 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
Набиране на участнициФаза 2
- Massachusetts General Hospital Cancer Center, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Набиране на участнициФаза 1/2
- Dana-Farber Cancer Institute, Boston
Project: Every Child for Younger Patients With Cancer
Набиране на участнициНаблюдателно проучване
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Набиране на участнициФаза 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Набиране на участнициФаза 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Набиране на участнициФаза 1/2
- Call for Information (Investigational Site 0026), Boston
Video Education With Result Dependent dIsclosure
Набиране на участници
- Dana Farber Cancer Institute, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Набиране на участнициФаза 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Набиране на участнициФаза 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Набиране на участнициФаза 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Набиране на участнициФаза 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Набиране на участнициФаза 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
Набиране на участнициФаза 1
- Dana Farber Cancer Institute, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Набиране на участнициФаза 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Набиране на участнициФаза 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Набиране на участнициФаза 2
- Dana Farber Cancer Institute, Boston
Проучвания за Меланом в други градове
- Houston, TX59 проучвания
- New York City, NY38 проучвания
- Los Angeles, CA34 проучвания
- Nashville, TN33 проучвания
- Pittsburgh, PA31 проучвания
- Philadelphia, PA23 проучвания
- San Francisco, CA22 проучвания
- Atlanta, GA21 проучвания
- Durham, NC21 проучвания
- St. Louis, MO21 проучвания
- Columbus, OH21 проучвания
- Salt Lake City, UT21 проучвания
Други проучвания в Boston
- Рак на гърдата111 проучвания
- Рак на белия дроб с недребноклетъчен тип90 проучвания
- Рак (всички видове)86 проучвания
- Колоректален рак63 проучвания
- Метастатичен рак63 проучвания
- Рак на белия дроб62 проучвания
- Рак на яйчниците61 проучвания
- Рак на простатата59 проучвания
- Депресия52 проучвания
- Ендометриален рак50 проучвания
- Сърдечна недостатъчност44 проучвания
- Остра миелоидна левкемия44 проучвания
От ClinicalTrials.gov, данни към 5.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.